A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Norway Opens Corruption Probe Into Former PM and Nobel Committee Chair Thorbjoern Jagland Over Epstein Links
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



